APP and Alzheimer disease: It is interesting that in an APP/PS1 transgenic mouse model of AD as well, Doxy’s positive effect on cognitive behavior was not immediately associated with a reduction in Aβ deposits when the drug was administered acutely or chronically for a relatively short time; the Aβ plaques were reduced only when treatment was prolonged to three months [267].